Celsius Therapeutics, a Cambridge, MA-based company translating single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer, launched with a $65m Series A financing.
The round was led by Third Rock Ventures with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and other key investors.
Launched in 2018, Celsius Therapeutics is charting a new course of target and drug discovery by understanding the specific cells, among many others, that are key players in disease and by identifying the genes that are triggering their malfunction. The company is applying a systematic approach to single-cell sequencing, combining datasets and complex algorithms in order to discover precision therapies for patients with autoimmune diseases and cancer.
Celsius was co-founded by:
– Jeffrey Bluestone, Ph.D., president and chief executive officer, Parker Institute for Cancer Immunotherapy, University of California, San Francisco; A.W. and Mary Margaret Clausen Distinguished Professor
– Vijay Kuchroo, D.V.M., Ph.D., Samuel L. Wasserstrom professor of neurology, Harvard Medical School; senior scientist, neurology, Brigham and Women’s Hospital; associate member, Broad Institute; director, Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women’s Hospital
– Christoph Lengauer, Ph.D., venture partner, Third Rock Ventures; president, Celsius Therapeutics; adjunct associate professor, Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine
– Aviv Regev, Ph.D., Chair of the Faculty and core institute member, and director, Klarman Cell Observatory, Broad Institute; professor, Department of Biology, MIT; Investigator, Howard Hughes Medical Institute
– Ramnik Xavier, M.D., chief of gastroenterology, Massachusetts General Hospital; institute member, Broad Institute; Kurt Isselbacher professor of medicine, Harvard Medical School.